RESUMEN
Purpose: Local recurrence predicts dismal prognosis in eyelid sebaceous carcinoma (SC). Recurrence predictors vary across studies. Accurate recurrence estimation is essential for individualized therapy in eyelid SC. This study aims to identify recurrence predictors and develop a nomogram for personalized prediction in eyelid SC. Methods: We conducted a multicenter retrospective cohort study. Chart reviews were performed in 418 consecutive patients with eyelid SC. All patients were followed up after their initial surgery. Multivariate Cox regression was used to explore the independent predictors of recurrence. A nomogram for recurrence prediction was developed and validated with bootstrap resampling. The predictive accuracy and discriminative ability were compared with the Tumor, Node, Metastasis (TNM) staging system. Results: Over a median of 60-month follow-up, 167 patients (40%) had local recurrence. The median time from diagnosis to recurrence was 14 months. The 1-year cumulative recurrence rate was 18%. Diagnostic delay (hazard ratio [HR] = 1.01, 95% confidence interval [CI] = 1.00-1.01, P = 0.001), orbital involvement (HR = 4.47, 95% CI = 3.04-6.58, P < 0.001), Ki67 (HR = 1.01, 95% CI = 1.00-1.02, P = 0.008) and initial surgery of Mohs micrographic surgery with intraoperative frozen section control (HR = 0.53, 95% CI = 0.35-0.80, P = 0.003) were independent influencing factors of recurrence. A nomogram integrating these four factors combined with pagetoid spread displayed satisfactory discriminative ability (C-index = 0.80-0.83; area under the curve [AUC] = 0.82-0.84), which compared favorably than TNM staging (all P < 0.05). Conclusions: The recurrence rate is high in eyelid SC. Early detection and primary resection with Mohs micrographic surgery are recommended in controlling recurrence. Patients with orbital involvement, high Ki67 expression, and pagetoid spread may require adjuvant measures. This nomogram offers more accurate recurrence estimates, aiding in therapeutic decision making.
Asunto(s)
Adenocarcinoma Sebáceo , Neoplasias de los Párpados , Recurrencia Local de Neoplasia , Nomogramas , Neoplasias de las Glándulas Sebáceas , Humanos , Masculino , Femenino , Estudios Retrospectivos , Neoplasias de los Párpados/patología , Neoplasias de los Párpados/diagnóstico , Neoplasias de las Glándulas Sebáceas/patología , Neoplasias de las Glándulas Sebáceas/diagnóstico , Persona de Mediana Edad , Anciano , Adenocarcinoma Sebáceo/patología , Adenocarcinoma Sebáceo/diagnóstico , Estudios de Seguimiento , Estadificación de Neoplasias , Anciano de 80 o más Años , Adulto , PronósticoRESUMEN
PURPOSE: To report the outcomes of platinum-based neoadjuvant chemotherapy (NACT) for eyelid and periocular sebaceous gland carcinoma (eSGC). METHODS: Retrospective study of 25 patients. RESULTS: The mean age at presentation of eSGC was 59 years. The mean tumor basal diameter was 46 mm. By the 8th edition of AJCC classification, tumors belonged T2 (n = 2, 8%), T3 (n = 6, 24%), and T4 (n = 17, 68%); N1 (n = 12,48%); and M1 (n = 1, 4%). NACT with 5-fluorouracil (5-FU) and cisplatin/carboplatin was administered in 21 (84%)/4 (16%) patients, respectively. The mean number of cycles of neoadjuvant systemic chemotherapy per patient was 2 (median, 3). The mean percentage reduction of tumor basal volume after neoadjuvant chemotherapy was 65% (median, 60%). After NACT, 12 (48%) patients underwent surgical treatment, 6 (12%) patients underwent EBRT, and 4 (8%) underwent adjuvant chemotherapy. A total of 11 (44%) patients were lost to follow-up during the course of treatment, of whom 3 died from metastatic disease. In 16 patients followed up for ≥ 3 months, complete tumor control was achieved in 11 (69%) patients, local tumor control in 14 (88%), and globe salvage in 7 (44%) at a mean follow-up of 25 months (median, 7 months; range, 3 to 110 months). No tumor recurrence was seen in any case. One (4%) serious adverse event of cardiotoxicity was noted. CONCLUSION: Platinum-based NACT is a suitable option for eSGC with advanced tumors and locoregional metastasis. Adverse events are rare and in patients compliant with treatment, NACT-based combination therapy offers globe salvage and systemic tumor control.
Asunto(s)
Neoplasias de los Párpados , Terapia Neoadyuvante , Neoplasias de las Glándulas Sebáceas , Humanos , Persona de Mediana Edad , Masculino , Femenino , Estudios Retrospectivos , Neoplasias de los Párpados/tratamiento farmacológico , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/patología , Neoplasias de las Glándulas Sebáceas/tratamiento farmacológico , Neoplasias de las Glándulas Sebáceas/cirugía , Neoplasias de las Glándulas Sebáceas/diagnóstico , Neoplasias de las Glándulas Sebáceas/patología , Terapia Neoadyuvante/métodos , Anciano , Adulto , Adenocarcinoma Sebáceo/tratamiento farmacológico , Adenocarcinoma Sebáceo/diagnóstico , Adenocarcinoma Sebáceo/patología , Adenocarcinoma Sebáceo/cirugía , Estudios de Seguimiento , Cisplatino/administración & dosificación , Cisplatino/uso terapéutico , Anciano de 80 o más Años , Fluorouracilo/administración & dosificación , Fluorouracilo/uso terapéutico , Quimioterapia Adyuvante/métodos , Carboplatino/administración & dosificación , Carboplatino/uso terapéutico , Estadificación de Neoplasias , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Resultado del TratamientoRESUMEN
Approximately 5-15% of all dermatologic malignancies manifest in the upper and lower eyelids. The primary types include basal cell carcinoma, squamous cell carcinoma, and sebaceous cell carcinoma, with Merkel cell carcinoma and melanoma following closely behind. Basal cell carcinoma predominantly affects the lower eyelid, yet various other carcinomas, melanomas, metastases, and neoplasms of diverse origins can arise on both upper and lower eyelids. Risk factors such as advanced age, smoking, and notably, exposure to UV light significantly contribute to the development of these eyelid lesions. Despite the increasing incidence, research on dermatologic eyelid malignancies remains limited. However, such study is imperative given that many systemic oncologic malignancies initially present as metastatic eyelid lesions. This paper provides an in-depth exploration of eyelid anatomy, clinical presentation, diagnosis, and treatment management.Key Points: Eyelid metastases represent less than one percent of all eyelid cancers, yet they often serve as the initial indication of an underlying systemic malignancy. Early detection and treatment is crucial in improving prognosis and quality of life for patients. Treatment options encompass a range of modalities, with Mohs surgery as the gold standard for the removal of ocular tumors. Additional treatment options include local excision as well as non-surgical interventions such as radiotherapy, cryotherapy, immunotherapy, and topical medications.
Asunto(s)
Neoplasias de los Párpados , Humanos , Neoplasias de los Párpados/terapia , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/epidemiología , Neoplasias de los Párpados/patología , Párpados/patología , Cirugía de Mohs , Neoplasias Cutáneas/terapia , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/epidemiología , Melanoma/terapia , Melanoma/diagnóstico , Melanoma/patología , Melanoma/epidemiología , Carcinoma de Células de Merkel/terapia , Carcinoma de Células de Merkel/diagnóstico , Carcinoma de Células de Merkel/epidemiología , Carcinoma de Células de Merkel/secundario , Carcinoma de Células de Merkel/patología , Factores de Riesgo , Carcinoma Basocelular/terapia , Carcinoma Basocelular/diagnóstico , Carcinoma Basocelular/epidemiología , Carcinoma Basocelular/patología , Carcinoma Basocelular/secundario , Calidad de Vida , Carcinoma de Células Escamosas/terapia , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/secundario , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/epidemiología , Neoplasias de las Glándulas Sebáceas/terapia , Neoplasias de las Glándulas Sebáceas/diagnóstico , Neoplasias de las Glándulas Sebáceas/patologíaRESUMEN
A man aged 73 years presented with a 5-day history of a fast-growing right eyebrow nodule with raised borders and central ulceration. There was no discomfort, and the patient denied vision changes. The lesion was refractory to treatment with erythromycin, clindamycin, and trimethoprim/sulfamethoxazole. What would you do next?
Asunto(s)
Neoplasias de los Párpados , Humanos , Masculino , Anciano , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/patología , Enfermedades de los Párpados/diagnóstico , Diagnóstico Diferencial , Párpados/patologíaRESUMEN
A 6-year-old male golden retriever presented with swelling of the left upper eyelid of 2 months duration, which did not improve following a course of antibiotics. Routine serum biochemistry, complete blood count and diagnostic imaging identified no clinically significant abnormalities. The mass was surgically excised, and histopathologic examination was performed. Eosinophilic granulocytic sarcoma (GS) was diagnosed based on the results of histopathology and immunohistochemistry. This is the first report of GS affecting the eyelid of a dog.
Asunto(s)
Enfermedades de los Perros , Sarcoma Mieloide , Animales , Perros , Masculino , Enfermedades de los Perros/cirugía , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/patología , Sarcoma Mieloide/veterinaria , Sarcoma Mieloide/diagnóstico , Sarcoma Mieloide/patología , Sarcoma Mieloide/cirugía , Neoplasias de los Párpados/veterinaria , Neoplasias de los Párpados/cirugía , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/patologíaAsunto(s)
Neoplasias de los Párpados , Humanos , Neoplasias de los Párpados/patología , Neoplasias de los Párpados/cirugía , Neoplasias de los Párpados/diagnóstico , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/diagnóstico , Nevo Pigmentado/patología , Nevo Pigmentado/diagnóstico , Masculino , FemeninoAsunto(s)
Neoplasias de los Párpados , Neoplasias de las Glándulas Sebáceas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adenocarcinoma Sebáceo/diagnóstico , Adenocarcinoma Sebáceo/inducido químicamente , Adenocarcinoma Sebáceo/tratamiento farmacológico , Neoplasias de los Párpados/tratamiento farmacológico , Neoplasias de los Párpados/diagnóstico , Neoplasias de las Glándulas Sebáceas/diagnóstico , Neoplasias de las Glándulas Sebáceas/inducido químicamente , Neoplasias de las Glándulas Sebáceas/tratamiento farmacológico , AdultoRESUMEN
Merkel cell carcinoma (MCC) is an unusual skin tumor that has a significant rate of distant and local metastases. It is known that primary MCC of the eyelid usually occurs at the upper eyelid. Here we report an unusual case of MCC metastasis to the eyelid. A 63-year-old male was diagnosed with MCC three years earlier after initially presenting with a mass in his right thigh. After histopathological diagnosis, the patient received medical therapy. During treatment, he developed multiple distant metastases and a firm, purple, vascularized lesion on the upper eyelid. We confirmed the lesion was an eyelid metastasis of MCC by histopathological examination and imaging methods. This case shows that extraocular MCC can metastasize to the eyelids, particularly the upper eyelid, where primary periocular MCC usually appears.
Asunto(s)
Carcinoma de Células de Merkel , Neoplasias de los Párpados , Neoplasias Cutáneas , Humanos , Masculino , Carcinoma de Células de Merkel/secundario , Carcinoma de Células de Merkel/diagnóstico , Persona de Mediana Edad , Neoplasias de los Párpados/secundario , Neoplasias de los Párpados/diagnóstico , Neoplasias Cutáneas/secundario , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Biopsia , Párpados/patologíaRESUMEN
ABSTRACT: Skin adnexal or sweat gland neoplasms are rare adnexal tumors that pose a diagnostic challenge for both ophthalmologists and pathologists. Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is an uncommon low grade carcinoma of eccrine ducts with a predilection to occur in the periocular region in the elderly female. We present a rare case of 65-year-old healthy male who presented with a lobulated mass in the left eye lower lid, clinically suspected as sebaceous gland carcinoma, diagnosed as endocrine mucin-producing sweat gland carcinoma histopathologically.
Asunto(s)
Neoplasias de los Párpados , Mucinas , Neoplasias de las Glándulas Sudoríparas , Humanos , Masculino , Anciano , Neoplasias de las Glándulas Sudoríparas/diagnóstico , Neoplasias de las Glándulas Sudoríparas/patología , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/patología , Párpados/patología , Diagnóstico Diferencial , Carcinoma/diagnóstico , Carcinoma/patología , InmunohistoquímicaRESUMEN
Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine tumor with a poor five-year survival rate. Yearly cases have risen nearly 350% since the early 1980s, and these are predicted to increase as the overall US population ages. MCC of the eyelid is uncommon and can be misdiagnosed as other benign inflammatory and neoplastic eyelid disorders. Although MCC of the head and neck is often more aggressive than it is at other sites, eyelid MCC shows a lower disease-specific mortality rate. A biopsy is essential for accurate diagnosis, including an immunohistochemical panel of CK20 and TTF-1, although other markers may be necessary. Staging can be assessed clinically through physical examination findings and imaging and/or pathologically with sentinel lymph node biopsy or fine-needle aspiration. Pathologic staging more accurately predicts the prognosis. Eyelid MCC treatments include Mohs micrographic surgery to allow for complete clearance and adequate reconstruction of lost tissue, followed by adjuvant radiotherapy. In advanced disease, immunotherapies are preferred over traditional chemotherapy and are a subject of ongoing research.
Asunto(s)
Carcinoma de Células de Merkel , Neoplasias de los Párpados , Neoplasias Cutáneas , Carcinoma de Células de Merkel/terapia , Carcinoma de Células de Merkel/diagnóstico , Carcinoma de Células de Merkel/patología , Humanos , Neoplasias de los Párpados/terapia , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/patología , Neoplasias Cutáneas/terapia , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Estadificación de Neoplasias , Cirugía de Mohs , Pronóstico , Radioterapia Adyuvante , InmunoterapiaRESUMEN
Periocular sebaceous carcinoma (PSC) is a rare, aggressive, and potentially metastatic adnexal malignancy. Due to the ability of PSC to resemble several benign and malignant conditions, diagnosis is often delayed or mistaken. In addition, even with a known diagnosis, choosing the right treatment is still an open debate. For this reason, we decided to review the most up-to-date literature on PSC and propose a dedicated procedural protocol to help clinicians when dealing with PSC. A PubMed search was carried out using the terms "Sebaceous Carcinoma", "Adnexal Periocular Cancer", "Sebaceous Carcinoma AND eyelid", "Periocular Sebaceous Carcinoma", and "Ocular Adnexa". Pertinent studies published in English from 1997 up to December 2022 were compared to the selection criteria and if suitable, included in this review. Through the initial search, 84 articles were selected. Of these, 36 were included in the final study. Several papers explored different diagnostic and therapeutic strategies regarding PSC diagnosis and management. In light of the current literature review and the multidisciplinary experience of three clinical centers, a dedicated procedural protocol is proposed. PSC diagnosis may be achieved through accurate clinical evaluation, but it requires histopathologic confirmation, which can be challenging. Dermoscopy, in vivo reflectance confocal microscopy, and optical coherence tomography may facilitate PSC clinical examination, while immunohistochemistry stains may support histological diagnosis. Appropriate disease staging is necessary before choosing the treatment, as local disease requires radically different treatment compared to advanced disease. In addition, recent innovations in nonsurgical treatments, including radio-chemotherapy, immunotherapy, and targeted therapy, may be a viable option in the most challenging cases.
Asunto(s)
Adenocarcinoma Sebáceo , Neoplasias de los Párpados , Estadificación de Neoplasias , Neoplasias de las Glándulas Sebáceas , Humanos , Neoplasias de las Glándulas Sebáceas/terapia , Neoplasias de las Glándulas Sebáceas/diagnóstico , Neoplasias de las Glándulas Sebáceas/patología , Neoplasias de los Párpados/terapia , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/patología , Adenocarcinoma Sebáceo/terapia , Adenocarcinoma Sebáceo/diagnóstico , Adenocarcinoma Sebáceo/patología , Dermoscopía , Diagnóstico DiferencialRESUMEN
BACKGROUND: The accurate detection of eyelid tumors is essential for effective treatment, but it can be challenging due to small and unevenly distributed lesions surrounded by irrelevant noise. Moreover, early symptoms of eyelid tumors are atypical, and some categories of eyelid tumors exhibit similar color and texture features, making it difficult to distinguish between benign and malignant eyelid tumors, particularly for ophthalmologists with limited clinical experience. METHODS: We propose a hybrid model, HM_ADET, for automatic detection of eyelid tumors, including YOLOv7_CNFG to locate eyelid tumors and vision transformer (ViT) to classify benign and malignant eyelid tumors. First, the ConvNeXt module with an inverted bottleneck layer in the backbone of YOLOv7_CNFG is employed to prevent information loss of small eyelid tumors. Then, the flexible rectified linear unit (FReLU) is applied to capture multi-scale features such as texture, edge, and shape, thereby improving the localization accuracy of eyelid tumors. In addition, considering the geometric center and area difference between the predicted box (PB) and the ground truth box (GT), the GIoU_loss was utilized to handle cases of eyelid tumors with varying shapes and irregular boundaries. Finally, the multi-head attention (MHA) module is applied in ViT to extract discriminative features of eyelid tumors for benign and malignant classification. RESULTS: Experimental results demonstrate that the HM_ADET model achieves excellent performance in the detection of eyelid tumors. In specific, YOLOv7_CNFG outperforms YOLOv7, with AP increasing from 0.763 to 0.893 on the internal test set and from 0.647 to 0.765 on the external test set. ViT achieves AUCs of 0.945 (95% CI 0.894-0.981) and 0.915 (95% CI 0.860-0.955) for the classification of benign and malignant tumors on the internal and external test sets, respectively. CONCLUSIONS: Our study provides a promising strategy for the automatic diagnosis of eyelid tumors, which could potentially improve patient outcomes and reduce healthcare costs.
Asunto(s)
Neoplasias de los Párpados , Humanos , Neoplasias de los Párpados/diagnóstico , Área Bajo la Curva , Costos de la Atención en SaludRESUMEN
A 62-year-old male was referred for evaluation of a painless right lower-eyelid lesion noted during routine glaucoma follow-up. The lesion had been present for 3 years with slow, gradual enlargement. What would you do next?
Asunto(s)
Neoplasias de los Párpados , Masculino , Humanos , Persona de Mediana Edad , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/cirugía , Neoplasias de los Párpados/patología , Párpados/patologíaRESUMEN
Adnexal neoplasms of the eyelid encompass a wide variety of benign and malignant tumors of sebaceous, follicular, and sweat gland origin. Due to the specialized structures of the eyelid, these neoplasms present differently when compared with those of other locations. Although most dermatologists and ophthalmologists are familiar with the commonly reported adnexal tumors of the eyelid, such as hidrocystoma, pilomatrixoma, and sebaceous carcinoma, many other adnexal neoplasms have been reported at this unique anatomic site. Accurate and timely identification of these neoplasms is essential, as alterations of eyelid anatomy and function can have a negative impact on eye health, vision, and quality of life. We review the clinical and histopathologic features of common and rare eyelid adnexal neoplasms and discuss proposed treatment options.
Asunto(s)
Neoplasias de los Párpados , Neoplasias de las Glándulas Sebáceas , Humanos , Neoplasias de los Párpados/patología , Neoplasias de los Párpados/diagnóstico , Neoplasias de las Glándulas Sebáceas/patología , Neoplasias de las Glándulas Sebáceas/diagnóstico , Neoplasias de Anexos y Apéndices de Piel/patología , Neoplasias de Anexos y Apéndices de Piel/diagnóstico , Neoplasias de las Glándulas Sudoríparas/patología , Neoplasias de las Glándulas Sudoríparas/diagnóstico , Pilomatrixoma/patología , Pilomatrixoma/diagnóstico , Hidrocistoma/patología , Hidrocistoma/diagnósticoRESUMEN
BACKGROUND: Angiosarcoma is an extremely rare malignant tumor. So far, only about 42 cases of angiosarcoma involving the eyelids have been reported. Eyelid angiosarcoma occurs more frequently in elderly Caucasian males and is prone to misdiagnosis. We present a case report in a young Asian male patient with eyelid angiosarcoma that was misdiagnosed as a chalazion. CASE PRESENTATION: A 46-year-old South Korean male with no underlying disease had a right lower lid mass. The lesion was initially misdiagnosed as a chalazion at a local clinic, but a diagnosis of eyelid angiosarcoma was made after the first biopsy trial. PET-CT was performed to ensure that there was no metastasis in the whole body. Surgical excision with enough surgical margin was used alone for treatment and reconstruction was performed with a tarsoconjunctival advancement flap (modified Hughes procedure), which helped ensure good cosmesis. No recurrence was observed 4 years and 5 months after the surgery. CONCLUSIONS: The current study presents the first case of chalazion-mimicked eyelid angiosarcoma in a young Asian male aged under 50 years. This case shows that even if a benign eyelid disease is suspected in a young patient, an incisional biopsy must be performed to confirm whether the lesion is malignant. Since the prognosis is good for the case of eyelid angiosarcoma, if there is no clear evidence of distal metastasis, surgical resection should be performed with an enough safety margin.
Asunto(s)
Chalazión , Neoplasias de los Párpados , Hemangiosarcoma , Anciano , Masculino , Humanos , Persona de Mediana Edad , Chalazión/diagnóstico , Neoplasias de los Párpados/diagnóstico , Neoplasias de los Párpados/cirugía , Neoplasias de los Párpados/patología , Hemangiosarcoma/diagnóstico , Hemangiosarcoma/cirugía , Hemangiosarcoma/patología , Tomografía Computarizada por Tomografía de Emisión de Positrones , Párpados/cirugía , Párpados/patologíaRESUMEN
This case report describes a diagnosis of pigmented squamous cell carcinoma in situ in a female patient aged 61 years who presented with a pigmented lesion on her medial canthus that had been growing over a 2-year period.
Asunto(s)
Carcinoma de Células Escamosas , Neoplasias de los Párpados , Humanos , Párpados/patología , Carcinoma de Células Escamosas/diagnóstico , Neoplasias de los Párpados/diagnósticoRESUMEN
BACKGROUND: Malignant tumors of the eyelid are much less frequent than benign eyelid alterations. These are frequently incidental findings without symptoms which are often overlooked or misinterpreted by patients. OBJECTIVE: This article gives an overview of clinical aspects, diagnostics and treatment of the five most common malignant eyelid tumors and exemplarily explains the essential principles of evidence-based treatment of malignant eyelid tumors. METHODS: This narrative review was prepared based on a selective literature search. The depiction of the treatment of eyelid tumors is supported by illustrations of clinical cases. RESULTS: The medical history and inspection provide initial indications of malignancy. Every eyelid change suspected of being malignant should be examined histologically to confirm a diagnosis. By far the most common malignant eyelid tumor in Europe is basal cell carcinoma, which metastasizes only in exceptional cases. Squamous cell carcinomas, sebaceous adenocarcinomas, melanomas and Merkel cell carcinomas occur much less frequently. In these cases, potential metastasis in particular must be considered when making the diagnosis and staging has to be initiated. Surgical excision into healthy tissue with tumor-free margins is the gold standard for malignant eyelid tumors. Non-surgical adjuvant or neoadjuvant forms of evidence-based treatment can be initiated based on the individual case to minimize the risk of recurrence and metastasis. CONCLUSION: It is essential to recognize eyelid changes at an early stage, to classify them correctly and to initiate the appropriate treatment. The interaction between the general condition and the personal needs of a patient as well as state of the art medicine are the keys to a good personalized treatment.